Clinical trial NCT04006730: Analysis of the Pharmaceutical Validation of Picc Line Installation Requests at the Nîmes University Hospital
Official title: Analysis of the Pharmaceutical Validation of Picc Line Installation Requests at the Nîmes University Hospital
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Parenteral Nutrition
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
First posted: 2019-07-05
Enrollment: 277
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The patients included in the study are patients aged at least 18 years old, hospitalized at the University Hospital of Nîmes and benefit from a pharmaceutical validation of the connected request for picc line in the Xplore® software.

Brief summary: The picc line is a central venous catheter inserted peripherally into a deep vein in the arm (cephalic, basilic or axillary) whose distal end is located at the junction of the superior vena cava / atrium.

It is installed for a minimum of 7 days (1), and can be stored for up to 6 months or more if it is functional. For treatments with an indication of more than 3 months, it is common practice to place an implantable catheter chamber. The main indications for picc line placement are: long-term antibiotic therapy, parenteral nutrition, chemotherapy or long-term venous approach when difficulties are encountered in applying a peripheral venous route to the patient.

Quickly adopted by medical teams, picc lines are not without risk, however, and three complications are mainly reported: catheter obstruction, deep vein thrombosis and infections.

In order to avoid any risk of unnecessary complications, it therefore seems appropriate to target the most appropriate device upstream of the procedure according to the provisional indication.

An inventory of pharmaceutical interventions carried out during picc line requests would make it possible to lay the foundations for considering actions to be implemented with the various services requesting picc line and proposals for improvement for the follow-up of patients with picc line to reduce the risk of complications.


Eligibility criteria: Inclusion Criteria:

* Patient aged 18 or over, hospitalized at the University Hospital of Nîmes
* Benefiting from a pharmaceutical validation of the demand for picc line connected

Exclusion Criteria:

* The patient is opposed to participating in this study

Primary outcomes:
measure: estimate the prevalence of requesting pharmaceutical interventions with a criticality greater than or equal to 2 accepted.
timeFrame: 2018
Secondary outcomes:
Other outcomes:
Locations:
city: Nîmes
country: France
facility: Chu Nimes
Study officials:
References:
citation: Chasseigne V, Buisson M, Serrand C, Leguelinel-Blache G, Kinowski JM, Goupil J, Beregi JP, Frandon J. Pharmaceutical Analysis of Peripherally Inserted Central Catheter Requests Increases the Use of Single-Lumen Catheters: A Prospective Pilot Study. J Patient Saf. 2022 Dec 1;18(8):e1238-e1242. doi: 10.1097/PTS.0000000000001065. Epub 2022 Aug 2.
citation: Buisson M, Leguelinel G, Bastide S, Beregi JP, Kinowski JM, Frandon J, Chasseigne V. A new clinical approach to improve the appropriate use of peripherally inserted central catheters: a prospective study. Eur J Hosp Pharm. 2021 Nov;28(Suppl 2):e134-e139. doi: 10.1136/ejhpharm-2020-002483. Epub 2021 Jan 7.